Regenicin, Inc., (OTC Bulletin Board: RGIN.OB) is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is currently working to bring the product candidate, PermaDerm®, to market. PermaDerm® is an exciting breakthrough technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns and wounds. The company is publicly traded with headquarters in New Jersey.